INNOVANCE Anti-Xa assaySimplify your anticoagulant testing
The INNOVANCE® Anti-Xa assay1 is an automated chromogenic assay for the quantitative determination of the activity of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) as well as rivaroxaban, apixaban and edoxaban concentrations in citrated human plasma. The INNOVANCE Anti-Xa assay1 combines a truly ready-to-use liquid reagent for heparin and DOAC testing, allowing 24/7 access to rapid, specific testing for anticoagulants. Unlike most commercially-available solutions, this assay requires no manual preparation or waiting time. INNOVANCE Anti-Xa assay has now been extended to test for edoxaban.
Benefits
- Liquid reagents require no manual preparation or reconstitution, allowing staff to concentrate on high-value tasks.
- Combined testing solution reduces handling, material, and ordering complexity for the lab.
- Single calibration curve for both types of heparin (UFH and LMWH) streamlines result interpretation and eliminates the risk of evaluation on the wrong curve.
- 24/7 access to rapid, specific testing for anticoagulants supports timely patient treatment.
- Robust assay design reduces susceptibility to interferences.
- Drug-specific standards sets for the DOACs rivaroxaban, apixaban and edoxaban allow for accurate measurement of drug concentrations in ng/mL.
- Broad and consistent assay range of 0.10 to 1.50 IU/mL for UF and LMW heparin, extendable up to 2.25 IU/mL by sample dilution.
- High lot-to-lot consistency that helps ensure consistent patient results over time.
- Liquid reagents require no manual preparation or reconstitution, allowing staff to concentrate on high-value tasks.
- Combined testing solution reduces handling, material, and ordering complexity for the lab.
- Single calibration curve for both types of heparin (UFH and LMWH) streamlines result interpretation and eliminates the risk of evaluation on the wrong curve.
Technical Details
The INNOVANCE Anti-Xa assay1 offers robust performance across all parameters. With its compact and ready-to-use configuration, the INNOVANCE Anti-Xa assay1 supports improved laboratory outcomes. It builds on the proven performance of the INNOVANCE Heparin assay and leverages the same proven components, but now also includes DOAC testing capabilities.
0.10–1.50 IU/mL
Consistent measuring range for UFH and LMWH, extendable up to 2.25 IU/mL by sample dilution
20–350 ng/mL
Measuring range for rivaroxaban, apixaban and edoxaban, extendable up to 700 ng/mL by sample dilution
1.0%
Within-device/lab CV of INNOVANCE Heparin LMW Control 1
2.48%
Within-device/lab CV of INNOVANCE Apixaban Control 11
2.13%
Within-device/lab CV of INNOVANCE Rivaroxaban Control 11
2.0 ng/mL
Within device/Lab SD for INNOVANCE Edoxaban Control 11
Within-device/lab CV (%) indicated for CS-2500 System. Assay performance can vary from country to country as well as corresponding to the system application of the respective assay. The values listed above are provided as examples only.
8 weeks
Stability once opened at 2–8°C
Evidence
Learn more about the individual INNOVANCE Anti-Xa assay components
By combining heparin and DOAC testing into one simple and easy-to-use assay, the INNOVANCE Anti-Xa assay1 streamlines handling, reduces order complexity, and offers labs an economical testing outcome.
Availability on Systems from Siemens Healthineers
For details on available assay applications or ordering information, download a copy of the hemostasis reagent portfolio catalogue.
Clinical Use
Why your lab should perform anti-Xa testing for anticoagulants
To monitor and manage bleeding risks, labs are asked to safeguard anticoagulant therapies such as heparin or direct oral anticoagulants (DOACs) by testing patients for a growing number of agents.
Downloads
Services
Related Products, Services & Resources
Solutions to meet the needs of every hemostasis lab
Let Siemens Healthineers power up your lab with a comprehensive portfolio of hemostasis products.
Have you powered up your lab with INNOVANCE reagents?
The INNOVANCE® line is an example of our longstanding commitment to help answer the concrete challenges of laboratories like yours.
PEPconnect
Find out more about the education and performance experience for healthcare professionals.
Not available for sale in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements.
Vandiver JW, Vondracek TG. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring. Hosp Pract. 2013;41(2):16-24.33
Liveris A, Bello RA, Friedmann P, Duffy MA, Manwani D, Killinger JS, Rodriquez D, Weinstein S. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2014;15(2):e72-9.
Adatya S, Uriel N, Yarmohammadi H, Holley CT, Feng A, Roy SS, Reding MT, John R, Eckman P, Zantek ND. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support. JACC Heart Fail. 2015;3(4):314-22.
van Roessel S, Middeldorp S, Cheung YW, Zwinderman AH, de Pont AC. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin. Neth J Med. 2014;72(6):305-10. Free access: http://www.njmonline.nl/getpdf.php?id=1463
Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.
